173 related articles for article (PubMed ID: 31084376)
1. Transient Lentiviral Vector Production Using a Packed-Bed Bioreactor System.
McCarron A; Donnelley M; McIntyre C; Parsons D
Hum Gene Ther Methods; 2019 Jun; 30(3):93-101. PubMed ID: 31084376
[TBL] [Abstract][Full Text] [Related]
2. Optimization of lentiviral vector production for scale-up in fixed-bed bioreactor.
Valkama AJ; Leinonen HM; Lipponen EM; Turkki V; Malinen J; Heikura T; Ylä-Herttuala S; Lesch HP
Gene Ther; 2018 Jan; 25(1):39-46. PubMed ID: 29345252
[TBL] [Abstract][Full Text] [Related]
3. Scalable Lentiviral Vector Production Using Stable HEK293SF Producer Cell Lines.
Manceur AP; Kim H; Misic V; Andreev N; Dorion-Thibaudeau J; Lanthier S; Bernier A; Tremblay S; Gélinas AM; Broussau S; Gilbert R; Ansorge S
Hum Gene Ther Methods; 2017 Dec; 28(6):330-339. PubMed ID: 28826344
[TBL] [Abstract][Full Text] [Related]
4. Development of a scalable process for high-yield lentiviral vector production by transient transfection of HEK293 suspension cultures.
Ansorge S; Lanthier S; Transfiguracion J; Durocher Y; Henry O; Kamen A
J Gene Med; 2009 Oct; 11(10):868-76. PubMed ID: 19618482
[TBL] [Abstract][Full Text] [Related]
5. Exploring nutrient supplementation and bioprocess optimization to improve the production of lentiviral vectors in serum-free medium suspension cultures.
Vaz TA; Rodrigues AF; Coroadinha AS
Biotechnol J; 2024 Jan; 19(1):e2300212. PubMed ID: 37903159
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of the Single-Use Fixed-Bed Bioreactors in Scalable Virus Production.
Lesch HP; Valonen P; Karhinen M
Biotechnol J; 2021 Jan; 16(1):e2000020. PubMed ID: 32971565
[TBL] [Abstract][Full Text] [Related]
7. Establishing functional lentiviral vector production in a stirred bioreactor for CAR-T cell therapy.
Tang QL; Gu LX; Xu Y; Liao XH; Zhou Y; Zhang TC
Bioengineered; 2021 Dec; 12(1):2095-2105. PubMed ID: 34047682
[TBL] [Abstract][Full Text] [Related]
8. Generation of stable suspension producer cell lines for serum-free lentivirus production.
Klimpel M; Terrao M; Bräuer M; Dersch H; Biserni M; Melo Do Nascimento L; Schwingal S; Vogel JE; Ferlemann C; Brandt T; Lal NI; Bridgeman K; Petzke A; McDwyer E; Lim JL; Oh S; Brumatti G; Garcia Minambres A; Otte E; Noll T; Pirzas V; Laux H
Biotechnol J; 2024 May; 19(5):e2400090. PubMed ID: 38719592
[TBL] [Abstract][Full Text] [Related]
9. Optimised protocols to generate high titre lentiviral vectors using a novel transfection agent enabling extended HEK293T culture following transient transfection and suspension culture.
Suleman S; Fawaz S; Roberts T; Ellison S; Bigger B; Themis M
J Virol Methods; 2024 Apr; 325():114884. PubMed ID: 38218417
[TBL] [Abstract][Full Text] [Related]
10. Characterization of lentiviral vector production using microwell suspension cultures of HEK293T-derived producer cells.
Guy HM; McCloskey L; Lye GJ; Mitrophanous KA; Mukhopadhyay TK
Hum Gene Ther Methods; 2013 Apr; 24(2):125-39. PubMed ID: 23461548
[TBL] [Abstract][Full Text] [Related]
11. Development of a perfusion process for continuous lentivirus production using stable suspension producer cell lines.
Klimpel M; Terrao M; Ching N; Climenti V; Noll T; Pirzas V; Laux H
Biotechnol Bioeng; 2023 Sep; 120(9):2622-2638. PubMed ID: 37148430
[TBL] [Abstract][Full Text] [Related]
12. Development and Optimization of AAV hFIX Particles by Transient Transfection in an iCELLis(®) Fixed-Bed Bioreactor.
Powers AD; Piras BA; Clark RK; Lockey TD; Meagher MM
Hum Gene Ther Methods; 2016 Jun; 27(3):112-21. PubMed ID: 27229773
[TBL] [Abstract][Full Text] [Related]
13. Benchmarking of Scale-X Bioreactor System in Lentiviral and Adenoviral Vector Production.
Leinonen HM; Lepola S; Lipponen EM; Heikura T; Koponen T; Parker N; Ylä-Herttuala S; Lesch HP
Hum Gene Ther; 2020 Mar; 31(5-6):376-384. PubMed ID: 32075423
[TBL] [Abstract][Full Text] [Related]
14. Scale-up and manufacturing of clinical-grade self-inactivating γ-retroviral vectors by transient transfection.
van der Loo JC; Swaney WP; Grassman E; Terwilliger A; Higashimoto T; Schambach A; Baum C; Thrasher AJ; Williams DA; Nordling DL; Reeves L; Malik P
Gene Ther; 2012 Mar; 19(3):246-54. PubMed ID: 21753795
[TBL] [Abstract][Full Text] [Related]
15. Depth filtration for clarification of intensified lentiviral vector suspension cell culture.
Mayani M; Nellimarla S; Mangalathillam R; Rao H; Patarroyo-White S; Ma J; Figueroa B
Biotechnol Prog; 2024; 40(2):e3409. PubMed ID: 37985144
[TBL] [Abstract][Full Text] [Related]
16. Lentiviral Vector Production from a Stable Packaging Cell Line Using a Packed Bed Bioreactor.
Powers AD; Drury JE; Hoehamer CF; Lockey TD; Meagher MM
Mol Ther Methods Clin Dev; 2020 Dec; 19():1-13. PubMed ID: 32995355
[TBL] [Abstract][Full Text] [Related]
17. Lentiviral Vector Bioprocessing.
Perry C; Rayat ACME
Viruses; 2021 Feb; 13(2):. PubMed ID: 33572347
[TBL] [Abstract][Full Text] [Related]
18. New protocol for lentiviral vector mass production.
Segura MM; Garnier A; Durocher Y; Ansorge S; Kamen A
Methods Mol Biol; 2010; 614():39-52. PubMed ID: 20225034
[TBL] [Abstract][Full Text] [Related]
19. Large-scale clinical-grade retroviral vector production in a fixed-bed bioreactor.
Wang X; Olszewska M; Qu J; Wasielewska T; Bartido S; Hermetet G; Sadelain M; Rivière I
J Immunother; 2015 Apr; 38(3):127-35. PubMed ID: 25751502
[TBL] [Abstract][Full Text] [Related]
20. Continuous manufacturing of lentiviral vectors using a stable producer cell line in a fixed-bed bioreactor.
Stibbs DJ; Silva Couto P; Takeuchi Y; Rafiq QA; Jackson NB; Rayat ACME
Mol Ther Methods Clin Dev; 2024 Mar; 32(1):101209. PubMed ID: 38435128
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
